文献速递特殊人群用药

质子泵抑制剂使用与痴呆风险关联的更新荟萃分析:方法学选择的影响

Evaluating the Association Between PPI Use and Dementia Risk Considering Methodological Choices: An Updated Meta‐Analysis
RSS 订阅 · Clinical Pharmacology & Therapeutics · 2026-10-29

合并风险比显示PPI使用与痴呆存在微弱关联(HR=1.18,95%CI 1.02–1.37),但该关联强度与特异性显著受对照选择和时间相关偏倚处理方式影响。

要点

  • PPI使用与痴呆风险呈微弱关联(HR=1.18,95%CI 1.02–1.37),但方法学选择显著影响估计值。
  • PPI使用者与H2RA使用者相比痴呆风险无显著差异(HR=1.04,95%CI 0.89–1.20)。
  • 排除H2RA治疗患者后PPI估计值增强(HR=1.75,95%CI 1.38–2.22),提示对照选择影响结果。

核心结论

  • PPI使用与痴呆风险存在微弱关联,但关联强度与特异性很大程度上取决于对照选择和时间相关偏倚的处理方式。
  • 需要采用活性对照的精心设计长期研究来明确该效应是否为PPI特有。

研究设计与样本

  • 对纵向观察性研究进行荟萃分析,检索MEDLINE、Embase和CENTRAL数据库自建库至2026年1月25日。
  • 进行亚组分析以处理方法学问题,包括时间相关偏倚和对照选择。

主要发现

  • 合并风险比显示PPI使用与痴呆存在微弱关联(HR=1.18,95%CI 1.02–1.37)。
  • PPI使用者与H2RA使用者之间痴呆风险无显著差异(HR=1.04,95%CI 0.89–1.20)。
  • 事后分析中H2RA使用本身与痴呆相关(HR=1.44,95%CI 1.07–1.93),排除H2RA治疗患者后PPI估计值增强(HR=1.75,95%CI 1.38–2.22)。
  • 按时间相关偏倚处理方式分层:滞后时间法HR=1.25(95%CI 1.07–1.46),时变暴露法HR=1.38(95%CI 1.16–1.64)。

临床怎么用

  • 临床解读PPI与痴呆关联证据时需考虑对照选择和时间相关偏倚处理方法对结果的影响。
  • 不应仅基于观察性关联改变PPI处方实践,需结合个体获益风险评估。

局限性

  • 纳入研究均为观察性设计,无法排除残余混杂。
  • 关联强度与特异性受方法学选择影响显著,提示结果稳健性有限。
  • 需要采用活性对照的精心设计长期研究以明确因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proton pump inhibitors (PPIs), commonly prescribed for gastrointestinal disorders, have been investigated for their association with the risk of dementia. We aimed to assess the association between PPI use and dementia risk in older adults and examine the influence of methodological choices on this association. We conducted a meta-analysis of longitudinal observational studies, including subgroup analyses to address time-related biases and comparator selection. Relevant studies were systematically searched in the MEDLINE, Embase, and CENTRAL databases from their inception to January 25, 2026. Twenty-three studies of older adults without dementia at baseline, reporting adjusted estimates for PPI users versus a comparator group, met the inclusion criteria. The pooled hazard ratio (HR) indicated a modest association between PPI use and dementia (HR = 1.18, 95% confidence interval [CI] 1.02–1.37). Dementia risk did not differ significantly between PPI users and users of histamine-2 receptor antagonists (H2RAs) (HR = 1.04, 95% CI 0.89–1.20). In a post hoc analysis, H2RA use itself was associated with dementia (HR = 1.44, 95% CI 1.07–1.93), whereas excluding H2RA-treated patients strengthened the PPI estimate (HR = 1.75, 95% CI 1.38–2.22). Estimates also differed according to how time-related bias was handled: lag time, HR = 1.25, 95% CI 1.07–1.46; time-varying exposure, HR = 1.38, 95% CI 1.16–1.64. PPI use was modestly associated with incident dementia. However, the strength and specificity depended substantially on comparator selection and handling of time-related bias. Well-designed, long-term studies using active comparators are needed to clarify whether this effect is PPI-specific.

来源:Clinical Pharmacology & Therapeutics,查看原文。版权归原作者所有。

引用

  1. Clinical Pharmacology & Therapeutics:Evaluating the Association Between PPI Use and Dementia Risk Considering Methodological Choices: An Updated Meta‐Analysis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。